Q-omics provides the consensus-scored RTL9 profile across patient tissues and cancer cell-line models. RTL9 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RTL9 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, RTL9 RNA expression shows 14,583 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, THCA, and THYM as cancer lineages where RTL9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RTL9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RTL9 survival associations across molecular data types. RTL9 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RTL9 RNA expression–survival associations across cancer types. High RTL9 expression shows unfavorable associations in STAD, KIRP and LUSC, but favorable associations in UVM, ACC and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RTL9 RNA expression.
This table summarizes RTL9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RTL9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RTL9 shows lower tumor expression in THCA, COAD, BLCA and PRAD and higher tumor expression in HNSC and LIHC. The THCA box plot shows higher RTL9 RNA expression in normal versus tumor tissue (log2 FC = −0.287, t-test p < 0.001).
This table shows molecular features associated with RTL9 in patient tissues and cancer cell lines. In patient samples, RTL9 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RTL9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
